Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04862507
Status:
RECRUITING
Last Update Posted:
2023-05-24
First Post:
2021-04-13
Brief Title:
Improving Low ASPECTS Stroke Thrombectomy
Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Organization:
Universitätsklinikum Hamburg-Eppendorf
Study Overview
Official Title:
Improving Low Alberta Stroke Program Early ct Score Stroke Thrombectomy
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
I-LAST
Brief Summary:
Improving Low ASPECTS Stroke Thromectomy I-LAST is an academic independent prospective multicenter observational registry study Consecutive patients treated with endovascular stroke treatment will be enrolled in German stroke centers Patients receive regular care and data will be collected as part of clinical routine Baseline clinical and procedural information as well clinical follow-up information during in-hospital stay and up to 90 days of stroke onset are collected Data collected include demographics National Institute of Health Stroke Scale NIHSS on admission pre-treatment ASPECTS information on timing and success of interventional treatment procedural complications intracranial hemorrhage and functional outcome Advanced imaging biomarkers will be tested and validated aiming to improve treatment selection and outcome prediction of patients presenting with extensive baseline infarction
Detailed Description:
This study aims to investigate the role of advanced imaging biomarkers in patients with large early infarct in particular quantitative lesion water uptake Minnerup et al Annals of Neurology 2016 arterial and venous collateral circulation Faizy et al Radiology 2021 and multivariate CTP-derived parameters Kemmling et al JCBFM 2015 The goal is to use these imaging biomarkers as specific selection criterion to predict clinical benefit after reperfusion despite extensive baseline infarct lesions also as a method of monitoring adjuvant neuroprotective agents after reperfusion therapy for instance anti-edematous medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None